Allarity Therapeutics - A new direction and name for Oncology Venture
It has been approximately a year since the new leadership took the reins of the company and this time of unprecedented change is capped-off with a name change from Oncology Venture to Allarity Therapeutics. It has streamlined its operations, focused on its priority assets and recapitalised itself in preparation of the upcoming NDA for dovitinib and start of studies for Ixempra. We are providing our clinical and commercial outlook with a valuation of SEK1,029m or SEK5.18 per share.Oncology Venture A/S, formerly known as Medical Prognosis Institute A/S, is a Denmark-based company engaged in the development of anticancer medicines. It is primarily focused on the tool development for identification of patients with the highest probability of responding to a particular drug candidate, which increases the chance that the drug candidate is to be successful in clinical trials. The Company aims to improve the response rate of anticancer medicines whose clinical development has been suspended. After the clinical trials, the Company is to out-license or sell the drug candidates with a high response rate. The Company's main drug candidates are comprised of APO010, Irofulven and LiPlaCis.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.